{"id":62597,"date":"2026-02-04T22:06:05","date_gmt":"2026-02-04T21:06:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/"},"modified":"2026-02-04T22:06:05","modified_gmt":"2026-02-04T21:06:05","slug":"neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

NEW YORK–(BUSINESS WIRE)–Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company\u2019s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company\u2019s common stock to one new employee (the \u201cInducement Grant\u201d) on February 2, 2026 (the \u201cGrant Date\u201d). The Inducement Grant has been granted pursuant to the Company\u2019s 2025 Inducement Plan. The Inducement Grant was granted as an inducement material to this individual entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n

\nThe Inducement Grant has an exercise price per share that is equal to the closing price of Neurogene\u2019s common stock on the Grant Date. The Inducement Grant will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and 1\/48 of the total award each month thereafter over the following three years, subject to the employee\u2019s continued employment with Neurogene through the applicable vesting dates.<\/p>\n

\nAbout Neurogene
\n
<\/b>The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company\u2019s novel and proprietary EXACT\u2122 transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit www.neurogene.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nCompany Contact:<\/b>
Mike Devine
\n
Executive Director, Corporate Communications
\n
michael.devine@neurogene.com<\/a><\/p>\n

Investor Contact:<\/b>
Argot Partners
\n
Neurogene@argotpartners.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company\u2019s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company\u2019s common stock … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62597","6":"format-standard","7":"category-industry"},"yoast_head":"\nNeurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW YORK–(BUSINESS WIRE)–Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company\u2019s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company\u2019s common stock ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T21:06:05+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-02-04T21:06:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":342,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2026-02-04T21:06:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","og_description":"NEW YORK–(BUSINESS WIRE)–Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company\u2019s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company\u2019s common stock ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Pharma Trend","article_published_time":"2026-02-04T21:06:05+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-02-04T21:06:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/"},"wordCount":342,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/","name":"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2026-02-04T21:06:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62597"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62597\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}